American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia
Research article published in Blood advances (2018)
Abstract
BACKGROUND: Heparin-induced thrombocytopenia (HIT) is an adverse drug reaction mediated by platelet-activating antibodies that target complexes of platelet factor 4 and heparin. Patients are at markedly increased risk of thromboembolism. OBJECTIVE: These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in their decisions about diagnosis and management of HIT. METHODS: ASH formed a multidisciplinary guideline panel balanced to minimize potential bias from conflicts of interest. The McMaster University GRADE Centre supported the guideline development process, including updating or performing systematic evidence reviews. The panel prioritized clinical questions and outcomes according to their importance for clinicians and patients. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to assess evidence and make recommendations, which were subject to public comment. RESULTS: The panel agreed on 33 recommendations. The recommendations address screening of asymptomatic patients for HIT, diagnosis and initial management of patients with suspected HIT, treatment of acute HIT, and special situations in patients with acute HIT or a history of HIT, including cardiovascular surgery, percutaneous cardiovascular intervention, renal replacement therapy, and venous thromboembolism prophylaxis. CONCLUSIONS: Strong recommendations include use of the 4Ts score rather than a gestalt approach for estimating the pretest probability of HIT and avoidance of HIT laboratory testing and empiric treatment of HIT in patients with a low-probability 4Ts score. Conditional recommendations include the choice among non-heparin anticoagulants (argatroban, bivalirudin, danaparoid, fondaparinux, direct oral anticoagulants) for treatment of acute HIT.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
Heparin-induced thrombocytopenia (HIT) is an adverse drug reaction mediated by platelet-activating antibodies that target complexes of platelet factor 4 and heparin.
Why This Matters for Hirudotherapy
These ASH clinical practice guidelines present 33 evidence-based recommendations, developed using GRADE methodology with systematic evidence reviews, for the diagnosis and management of heparin-induced thrombocytopenia (HIT). Among their conditional recommendations, the guidelines address selection among non-heparin anticoagulants for acute HIT treatment—including bivalirudin, a direct thrombin inhibitor and synthetic analog of hirudin, the signature anticoagulant in medicinal leech saliva. For the ASH/hirudotherapy community, this is genuinely relevant because it illustrates a major clinical scenario in which a pharmacological descendant of the leech secretome is explicitly positioned within mainstream hematology practice. The important caveat is that the guideline addresses HIT management broadly and does not evaluate hirudotherapy or native leech-derived hirudin; bivalirudin's inclusion reflects its established role as a licensed pharmaceutical, not any endorsement of leech therapy itself.
Citation
American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia
Cuker A et al. · Blood advances, 2018
Added to ASH library: May 27, 2026 · Site last updated: June 18, 2026